Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) Return on Capital Employed (2018 - 2025)

Crinetics Pharmaceuticals has reported Return on Capital Employed over the past 8 years, most recently at 0.48% for Q4 2025.

  • Quarterly results put Return on Capital Employed at 0.48% for Q4 2025, down 18.0% from a year ago — trailing twelve months through Dec 2025 was 0.48% (down 18.0% YoY), and the annual figure for FY2025 was 0.43%, down 8.0%.
  • Return on Capital Employed for Q4 2025 was 0.48% at Crinetics Pharmaceuticals, down from 0.41% in the prior quarter.
  • Over the last five years, Return on Capital Employed for CRNX hit a ceiling of 0.28% in Q1 2025 and a floor of 0.71% in Q2 2023.
  • Median Return on Capital Employed over the past 5 years was 0.4% (2021), compared with a mean of 0.42%.
  • Biggest five-year swings in Return on Capital Employed: plummeted -32bps in 2023 and later soared 40bps in 2024.
  • Crinetics Pharmaceuticals' Return on Capital Employed stood at 0.41% in 2021, then decreased by -21bps to 0.49% in 2022, then rose by 24bps to 0.37% in 2023, then rose by 20bps to 0.3% in 2024, then plummeted by -60bps to 0.48% in 2025.
  • The last three reported values for Return on Capital Employed were 0.48% (Q4 2025), 0.41% (Q3 2025), and 0.34% (Q2 2025) per Business Quant data.